Ventyx Biosciences to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Rhea-AI Summary

Ventyx Biosciences, Inc. (Nasdaq: VTYX) announced that its executives will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023. The company focuses on advancing novel oral therapies for inflammatory diseases with unmet medical needs. The webcast of the presentation will be available on the Ventyx website, with a replay available for thirty days.

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference being held on August 9, 2023.

• Event: Canaccord Genuity 43rd Annual Growth Conference
  Location: Boston, MA
  Date: Wednesday, August 9, 2023
  Time: 4:30-4:55 PM ET

A webcast of the presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for thirty days.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit www.ventyxbio.com.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com

FAQ

What is Ventyx Biosciences, Inc. focused on?

Ventyx Biosciences, Inc. is focused on advancing novel oral therapies for a broad range of inflammatory diseases with significant unmet medical need.

Where can I find the webcast of the presentation?

The webcast of the presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com.

How long will the webcast replay be available?

The webcast replay will be available on the Ventyx website shortly after the conclusion of the event for thirty days.